CombiGene
2.46
SEK
+3.36 %
Less than 1K followers
COMBI
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+3.36%
+7.89%
+3.36%
-8.89%
-1.6%
-32.42%
-73.83%
-73.61%
-97.44%
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Read moreMarket cap
48.71M SEK
Turnover
117.9K SEK
Revenue
330K
EBIT %
-14,309.09 %
P/E
-
Dividend yield-%
-
Financial calendar
17.6
2025
General meeting '25
22.8
2025
Interim report Q2'25
13.2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Year-end report January-December 2024 CombiGene AB (Publ)
Discontinuation of research activities
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools